ScreenerHero

CNTB Connect Biopharma Holdings Limited

NAS · US · Healthcare · Biotechnology · connectbiopharm.com
0.9447USD+4.34%Mkt Cap: 59.49M $P/E: —

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap59.49M USD
Enterprise Value26.13M USD
Revenue (TTM)2.95M USD
Gross Profit2.95M USD
Net Income (TTM)-55.48M USD
Revenue/Share0.05 USD
Last Price0.9447 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees64
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.30
PEG—
EV/EBITDA-0.38
EV/Revenue8.85
P/S19.31
P/B2.12
EPS (TTM)-1.19
EPS (Forward)-0.70
52W Range
0.85013% of range3.820
52W High3.820 USD
52W Low0.8501 USD
Profitability
Gross Margin100.00%
Oper. Margin-635.98%
EBITDA Margin0.00%
Profit Margin-86687.50%
ROE-132.16%
ROA-98.94%
Growth
Revenue Growth5666.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.21M USD
CapEx (TTM)434.00K USD
FCF Margin-1175.51%
FCF Yield-58.35%
Net Debt-30.89M USD
Net Debt/EBITDA0.44
Balance Sheet
Debt/Equity0.02
Current Ratio2.37
Quick Ratio2.11
Book Value/Sh0.43 USD
Cash/Share0.50 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.875 USD
Upside (mean)+521.9%
Target Range4.000 USD – 9.000 USD
4.000+521.9% to mean9.000
# Analysts8
Ownership
Shares Out.62.97M
Float21.57M
Insiders29.70%
Institutions56.13%
Short Interest
Short Ratio1.7d
Short % Float6.25%
Short % Out.4.41%
Shares Short2.77M
Short (prev mo.)1.82M
Technical
SMA 501.879 (-49.7%)
SMA 2002.342 (-59.7%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)7.09M
Avg Vol (10d)18.75M
Technical Indicators
RSI (14)31.8
MACD-0.3051
MACD Signal-0.2988
MACD Hist.-0.0063
BB Upper2.113 USD
BB Middle1.290 USD
BB Lower0.4676 USD
BB Width127.52%
ATR (14)0.2113 USD
Vol Ratio (20d)0.12x